GENOCEA BIOSCIENCES, INC.
GNCA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GNCA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2022.
Tracking 2 pipeline candidates for GENOCEA BIOSCIENCES, INC..
Run GENOCEA BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GENOCEA BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
4.3 months
D/E 2.13 · 21% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is GENOCEA BIOSCIENCES, INC.'s lead drug candidate?
GENOCEA BIOSCIENCES, INC.'s most advanced tracked candidate is gen-009 (Phase 2) for Solid tumors.
Who is the CEO of GENOCEA BIOSCIENCES, INC.?
William Clark is the chief executive officer of GENOCEA BIOSCIENCES, INC. (GNCA).
What therapeutic areas does GENOCEA BIOSCIENCES, INC. focus on?
GENOCEA BIOSCIENCES, INC. develops therapies across Oncology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.